Back to top
more

CanFite Biopharma (CANF)

(Delayed Data from AMEX)

$2.07 USD

2.07
20,092

-0.03 (-1.43%)

Updated Apr 15, 2024 03:59 PM ET

After-Market: $2.07 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (153 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CANF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Can-Fite Biopharma Ltd [CANF]

Reports for Purchase

Showing records 1 - 20 ( 216 total )

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 1

04/01/2024

Daily Note

Pages: 5

Termination of Coverage

Provider: Dawson James Securities, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 2

02/07/2024

Company Report

Pages: 4

High-Value Deal With Ewopharma Expanded to Include Pancreatic Cancer

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 3

01/29/2024

Company Report

Pages: 5

BUY: COMFORT-PIII Psoriasis Data Published in the Journal of the European Academy of Dermatology and Venereology

Provider: Dawson James Securities, Inc.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 4

12/18/2023

Company Report

Pages: 5

BUY: FDA - Green Light Piclidenoson in Kids

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 5

12/13/2023

Company Report

Pages: 5

BUY: Valuation Rolls Forward - New Shares Registered

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 6

12/04/2023

Company Report

Pages: 5

BUY: Life is Precious - That’s What Can-Fite Thinks - Pancreatic Cancer Trial Set to Advance.

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 7

11/30/2023

Company Report

Pages: 5

BUY: Reports 3rd Quarter Results: Spends $1.1M, $11M in Cash

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 8

11/03/2023

Company Report

Pages: 5

BUY: All Clinical Programs BD Are On Track

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 9

10/24/2023

Company Report

Pages: 5

Entry Into Rare Disease Field Could Enhance Piclidenoson’s Value; Reiterate Buy With an Adjusted PT of $18

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 10

08/31/2023

Company Report

Pages: 5

BUY: Reports 2nd Quarter Results: $9.6M in Cash

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 11

07/18/2023

Company Report

Pages: 5

BUY: Namodenoson: Liver Cancer at ASCO Japan

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 12

06/29/2023

Company Report

Pages: 5

BUY: Going Pivotal - Two US-Based Psoriasis Trials Including Adolescents

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 13

06/15/2023

Company Report

Pages: 5

BUY: Extending Namodenoson to Pancreatic Cancer

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 14

06/02/2023

Company Report

Pages: 5

Preparing for a Pivotal Year; Reiterate Buy and $34 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 15

06/01/2023

Company Report

Pages: 5

BUY: Reports First Quarter - Provides Clinical Snapshot

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 16

05/30/2023

Company Report

Pages: 5

Bluejay Reports First Quarter Results

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 17

05/01/2023

Company Report

Pages: 5

Raising to Buy from Neutral - $6.0 Price Target

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 18

04/10/2023

Company Report

Pages: 5

Neutral: Piclidenoson Gets the Go-Ahead to Start PIII Trial

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 19

03/13/2023

Daily Note

Pages: 3

Results With Compassionate Namodenoson Use in Decompensated Liver Cirrhosis Could Be Positive: Reit Buy and $34 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 20

01/27/2023

Company Report

Pages: 5

Piclidenoson and Namodenoson Continue With Strong Momentum Going Into 2023; Reit Buy With Post-ADS Adjusted Ratio $34 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party